Pet/ct imaging of chemokine receptor ccr5 in vascular injury model using targeted nanoparticle

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 629-634

  Luehmann, Hannah P ^a   Pressly, Eric D ^b   Detering, Lisa ^a   Wang, Cynthia ^b   Pierce, Richard ^a   Woodard, Pamela K ^a   Gropler, Robert J ^a   Hawker, Craig J ^b   Liu, Yongjian ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; CCR5; Chemokine receptor; Nanoparticles; PET CT

Indexed keywords

CHEMOKINE RECEPTOR CCR5; COPPER DOTA DEXTRO ALANINE 1 PEPTIDE T AMIDE CU 64; COPPER DOTA DEXTRO ALANINE 1 PEPTIDE T AMIDE POLY(METHYL METHACRYLATE)CORE POLYETHYLENE GLYCOL SHELL AMPHIPHILIC COMBLIKE NANOPARTICLE CU 64; COPPER DOTA POLY(METHYL METHACRYLATE)CORE POLYETHYLENE GLYCOL SHELL AMPHIPHILIC COMBLIKE NANOPARTICLE CU 64; NANOPARTICLE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG UPTAKE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MOUSE; NANOIMAGING; NONHUMAN; POLYMERIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ATHEROSCLEROSIS; CCR5; CHEMOKINE RECEPTOR; NANOPARTICLES; PET/CT;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BINDING, COMPETITIVE; COPPER RADIOISOTOPES; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASCULAR DISEASES;

EID: 84901340029     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.132001     Document Type: Article

References (33)

1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138.
2. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18:4266-4288.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
4. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1009-1016.
5. Deguchi JO, Aikawa M, Tung CH, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114:55-62.
6. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
7. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol. 2009;29:983-991.
8. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111:231-244.
9. Perrone-Filardi P, Dellegrottaglie S, Rudd JH, et al. Molecular imaging of atherosclerosis in translational medicine. Eur J Nucl Med Mol Imaging. 2011;38:969-975.
10. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med. 2010;51(suppl 1):33S-37S.
11. Boersma HH, de Haas HJ, Reutelingsperger CP, Slart RH. P-selectin imaging in cardiovascular disease: what you see is what you get? J Nucl Med. 2011; 52:1337-1338.
12. Dimastromatteo J, Broisat A, Perret P, et al. In vivo molecular imaging of atherosclerotic lesions in ApoE2/2 mice using VCAM-1-specific, 99mTc-labeled peptidic sequences. J Nucl Med. 2013;54:1442-1449.
13. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871-878.
14. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897-1908.
15. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621.
16. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol. 2004;15:145-149.
17. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65:47-89.
18. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-194.
19. Quinones MP, Martinez HG, Jimenez F, et al. CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis. 2007;195:e92-e103.
20. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469.
21. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov. 2010;9:141-153.
22. Liu Y, Pierce R, Luehmann HP, Sharp TL, Welch MJ. PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis. J Nucl Med. 2013;54:1135-1141.
23. Rosi S, Pert CB, Ruff MR, McGann-Gramling K,Wenk GL. Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience. 2005;134:671-676.
24. Polianova MT, Ruscetti FW, Pert CB, Ruff MR. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 2005;67:83-92.
25. Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. Bioconjug Chem. 2012;23:671-682.
26. Pressly ED, Rossin R, Hagooly A, et al. Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined 64Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules. 2007;8:3126-3134.
27. Liu Y, Pressly ED, Abendschein DR, et al. Targeting angiogenesis using a Ctype atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011;52:1956-1963.
28. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007;27:2079-2093.
29. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosisprone mice: involvement of IL-10. Blood. 2006;107:4240-4243.
30. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010;86:192-201.
31. Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res. 2003;1:51-67.
32. Mueller A, Kelly E, Strange PG. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood. 2002;99:785-791.
33. Pressly ED, Pierce RA, Connal LA, Hawker CJ, Liu Y. Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. Bioconjug Chem. 2013;24:196-204.